コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r systemic delivery of macromolecules from a transdermal patch.
2 st that can be administered once daily or by transdermal patch.
3 A shorter acting contraceptive option is the transdermal patch.
4 d in 10 weeks of treatment with the nicotine transdermal patch (21 mg/day) and 10 weekly group therap
6 on to sustained release oral medication, the transdermal patch and the intravaginal route are startin
7 rder who were also treated with the nicotine transdermal patch and with either atypical or typical an
8 delivery that are inspired by the design of transdermal patches and demonstrate their capabilities i
9 replacement group received a 21-mg nicotine transdermal patch, and those in the placebo group were t
10 1) smoking cessation rates with the nicotine transdermal patch are modest in schizophrenia, 2) specia
11 sublingual spray, transdermal ointment, and transdermal patch, as well as intravenous formulations.
13 To demonstrate the approach, we incorporated transdermal patches containing the contraceptive hormone
14 raceptive methods (oral contraceptive pills, transdermal patch, contraceptive vaginal ring, and depot
15 nicotine (TNP; n=37) or placebo (PBO; n=43) transdermal patch following overnight abstinence complet
16 ical agents in combination with the nicotine transdermal patch for smoking cessation in schizophrenia
18 stems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants a
19 hormonal contraceptive systems that include transdermal patches, intravaginal rings (IVRs), intraute
20 introduce pharmaceutical jewelry, in which a transdermal patch is incorporated into jewelry worn on s
21 mine agonist, is currently administered as a transdermal patch (Neupro(R)) for PD treatment, but the
22 randomized, crossover trial that compared a transdermal patch of ABT-418 (75 mg/day) to placebo in a
23 ording to DSM-IV, were randomized to receive transdermal patches of 17beta-estradiol (100 microgram)
24 randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in a
25 been fabricated and envisioned for use with transdermal patches or infusion pumps to achieve painles
26 up to 8-weeks treatment with NRT (15 mg/16 h transdermal patches) or identically packaged and visuall
28 st that can be administered once daily or by transdermal patch seems to be a reasonable option to con
29 tic agents, in combination with the nicotine transdermal patch, significantly enhanced the rate of sm